What scenarios, if any, are you delaying adjuvant chemotherapy in light of the COVID-19 outbreak?  

This is a complex issue that our group here at MSKCC is dealing with right now, with formalized guidance pending. This is in mind of the fact that the mortality rate in Chinese patients with cancer approached 6%. While I wouldn't delay starting adjuvant therapy—which is being given with curati...